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1. Introduction {#ehf212539-sec-0004}
===============

Digoxin is recommended in patients with heart failure with reduced ejection fraction (HFrEF) who continue to be symptomatic despite optimal therapy including angiotensin‐converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta‐blockers, mineralocorticoid receptor antagonists (MRAs), and diuretics as needed for fluid control or rate control in the presence of atrial fibrillation (AF).[1](#ehf212539-bib-0001){ref-type="ref"}, [2](#ehf212539-bib-0002){ref-type="ref"} Available randomized clinical trials have shown that digoxin improved clinical symptoms and lowered rates of hospitalization for HF but did not improve survival.[3](#ehf212539-bib-0003){ref-type="ref"}, [4](#ehf212539-bib-0004){ref-type="ref"}, [5](#ehf212539-bib-0005){ref-type="ref"}, [6](#ehf212539-bib-0006){ref-type="ref"}, [7](#ehf212539-bib-0007){ref-type="ref"}, [8](#ehf212539-bib-0008){ref-type="ref"} It is of note that almost all these trials were performed prior to conventional use of modern HF therapies including beta‐blockers, MRAs, and device therapies (e.g. implantable cardioverter--defibrillators and cardiac resynchronization therapy); thus, cautions are needed to translate previous study results of digoxin into today\'s clinical practice. In the meantime, recent studies based on either registry database or retrospective analysis showed that digoxin use was associated with increased risk of all‐cause mortality in HFrEF patients.[9](#ehf212539-bib-0009){ref-type="ref"}, [10](#ehf212539-bib-0010){ref-type="ref"}, [11](#ehf212539-bib-0011){ref-type="ref"}, [12](#ehf212539-bib-0012){ref-type="ref"}, [13](#ehf212539-bib-0013){ref-type="ref"} As the use of digoxin varied according to country and ethnicity,[14](#ehf212539-bib-0014){ref-type="ref"}, [15](#ehf212539-bib-0015){ref-type="ref"}, [16](#ehf212539-bib-0016){ref-type="ref"}, [17](#ehf212539-bib-0017){ref-type="ref"}, [18](#ehf212539-bib-0018){ref-type="ref"}, [19](#ehf212539-bib-0019){ref-type="ref"} in particular in China where the majority of HFrEF patients were treated with digoxin, and some traditional Chinese medicines (TCMs), for example, qili qiangxin capsules, had been shown effective in surrogate endpoints and thus have been recommended by current Chinese guideline for HF, which might interfere with digoxin use.[1](#ehf212539-bib-0001){ref-type="ref"}, [20](#ehf212539-bib-0020){ref-type="ref"}, [21](#ehf212539-bib-0021){ref-type="ref"} Therefore, there are great concern about both efficacy and safety of digoxin in the context of contemporary management of HFrEF in China.

Data of this study were derived from the China National Heart Failure Registration Study (CN‐HF). The present study aimed to analyse the impact of digoxin use on the outcomes of patients with HFrEF and its possible interaction with AF or use of currently guideline‐recommended treatments (ACEIs/ARBs, beta‐blockers, MRAs) in China.

2. Methods {#ehf212539-sec-0005}
==========

2.1. Study population {#ehf212539-sec-0006}
---------------------

The CN‐HF (ID: NCT02079428) was a nationwide, multicentre, prospective registry study that included patients with HF from 45 participating centres across nine regions in China between January 2013 and December 2015. Diagnostic criteria of HF were based on 2014 Chinese guidelines for the diagnosis and treatment of chronic HF.[1](#ehf212539-bib-0001){ref-type="ref"} The patients were followed up for 6, 12, 24, and 36 months after discharge, and the registrations were managed through online electronic system. Informed consent was obtained from all patients.

In this study, patients were eligible if left ventricular ejection fraction (LVEF) was 40% or less. Patients with significant renal dysfunction (creatinine \> 3.0 mg/dL), potassium \< 3.2 mmol/L or potassium \> 5.5 mmol/L, or withdrawal after short‐term oral digoxin treatment (≤30 days) were excluded.

The study conformed to the Declaration of Helsinki and was approved by all participating hospital ethics committees.

2.2. Data collection {#ehf212539-sec-0007}
--------------------

Data regarding demographic information, physical examination, laboratory index, echocardiography, co‐morbidities, medications, and clinical outcomes were obtained from CN‐HF. Patients were divided into two groups on the basis of the use of digoxin: non‐digoxin group and digoxin group. The primary endpoint of this study was all‐cause mortality; the secondary endpoints were HF mortality, all‐cause re‐hospitalization, and HF re‐hospitalization.

2.3. Statistical analyses {#ehf212539-sec-0008}
-------------------------

Continuous variables were presented as mean values with standard deviations (mean ± SD) or median (interquartile range), whereas categorical variables were displayed as counts and percentages. Differences between the two groups were compared using Student\'s *t*‐test or Mann--Whitney *U* test for continuous variables and the *χ* ^2^ test for categorical variables. Kaplan--Meier curves and log‐rank test were used to describe and compare time to events. Cox proportional‐hazards regression models were used to examine the independent association of digoxin use and the risk of adverse outcomes, and the following covariates were included in the model: age, systolic blood pressure (SBP), LVEF, New York Heart Association (NYHA) class, sodium, potassium, creatinine, haemoglobin, AF, and the use of digoxin, ACEIs/ARBs, beta‐blockers, and MRAs. Additional models were performed by concurrent use of other drugs (ACEIs/ARBs, beta‐blockers, and MRAs), with or without AF.

All *P*‐values reported were two‐sided, and *P* \< 0.05 was considered statistically significant. Statistical calculations were performed using SPSS software version 23.0.

3. Results {#ehf212539-sec-0009}
==========

3.1. Study population {#ehf212539-sec-0010}
---------------------

A total of 7171 patients were registered in CN‐HF: 5580 patients with LVEF available and 1332 defined as HFrEF. Among HFrEF patients, 74 were excluded owing to renal dysfunction, 92 due to potassium \< 3.2 mmol/L or potassium \> 5.5 mmol/L, 79 due to unknown digoxin medication status, and 205 due to withdrawal after short‐term oral digoxin (≤30 days). Finally, 882 patients were included in this study, with 372 (42.2%) patients in the digoxin group and 510 (57.8%) patients in the non‐digoxin group (*Figure* [*1*](#ehf212539-fig-0001){ref-type="fig"}). Among the 232 (26.3%) patients with AF, the use of ACEIs/ARBs, beta‐blockers, and MRAs was as high as 79.9%, 70.3%, and 89.0%, respectively. Regarding digoxin dose, 6.7%, 0.3%, 89.5%, and 1.3% of patients were treated with 0.25, 0.125--0.25, 0.125, and 0.0625 mg/day, respectively, whereas for the rest of 2.2% of patients, the dose of digoxin was unknown.

![Flowchart of the study population. LVEF, left ventricular ejection fraction.](EHF2-7-138-g001){#ehf212539-fig-0001}

3.2. Baseline characteristics {#ehf212539-sec-0011}
-----------------------------

Patients who received digoxin were younger and had lower LVEF, less co‐morbidities of hypertension and myocardial infarction, and less statins and aspirin use but had higher heart rate, higher NYHA class and haemoglobin level, higher co‐morbidity of AF, and more MRAs use (*Table* [1](#ehf212539-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics of the study population

  Characteristics         All (*n* = 882)   Non‐digoxin (*n* = 510)   Digoxin (*n* = 372)   *P* value
  ----------------------- ----------------- ------------------------- --------------------- -----------
  Age (years)             64.9 ± 14.2       66.1 ± 13.7               63.3 ± 14.8           0.004
  Female                  233 (26.4%)       125 (24.5%)               108 (29.0%)           0.132
  Heart rate (bpm)        85.7 ± 19.4       83.2 ± 18.6               89.1 ± 20.0           \<0.001
  SBP (mmHg)              126.3 ± 21.3      127.3 ± 21.2              125.0 ± 21.4          0.121
  NYHA class                                                                                \<0.001
  I                       20 (2.3%)         17 (3.3%)                 3 (0.8%)              
  II                      197 (22.3%)       142 (27.8%)               55 (14.8%)            
  III                     459 (52.0%)       238 (46.7%)               221 (59.4%)           
  IV                      206 (23.4%)       113 (22.2%)               93 (25.0%)            
  LVEF (%)                31.9 ± 6.6        32.7 ± 6.4                30.7 ± 6.7            \<0.001
  Na (mmol/L)             139.8 ± 6.0       140.1 ± 4.0               139.3 ± 8.0           0.059
  K (mmol/L)              4.1 ± 0.5         4.1 ± 0.5                 4.1 ± 0.5             0.554
  Cr (umol/L)             1.1 (0.8,1.3)     1.0 (0.9,1.3)             1.0 (0.8,1.3)         0.137
  Hb (g/L)                131.3 ± 19.7      129.6 ± 19.4              133.7 ± 19.2          0.002
  Co‐morbidities                                                                            
  Hypertension            451 (51.1%)       279 (54.7%)               172 (46.2%)           0.013
  Myocardial infarction   188 (21.3%)       133 (26.1%)               55 (14.8%)            \<0.001
  Hyperlipidaemia         80 (9.1%)         49 (9.6%)                 31 (8.3%)             0.515
  Diabetes mellitus       217 (24.6%)       126 (24.7%)               91 (24.5%)            0.934
  AF                      232 (26.3%)       111 (21.8%)               121 (32.5%)           \<0.001
  Medications                                                                               
  ACEIs/ARBs              705 (79.9%)       409 (80.2%)               296 (79.6%)           0.819
  Beta‐blockers           620 (70.3%)       362 (71.0%)               258 (69.4%)           0.602
  MRAs                    785 (89.0%)       429 (84.1%)               356 (95.7%)           \<0.001
  Nitrates                429 (48.6%)       245 (48.0%)               184 (49.5%)           0.676
  Statins                 403 (45.7%)       251 (49.2%)               152 (40.9%)           0.014
  Aspirin                 462 (52.4%)       287 (56.3%)               175 (47.0%)           0.007
  TCM                     159 (18.0)        84 (16.5%)                75 (20.2%)            0.159

ACEIs, angiotensin‐converting enzyme inhibitors; AF, atrial fibrillation; ARBs, angiotensin receptor blockers; Cr, Creatinine; Hb, Haemoglobin; K, serum potassium; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; Na, serum sodium; NYHA, New York Heart Association; SBP, systolic blood pressure; TCM, traditional Chinese medicine.

3.3. Outcome analysis {#ehf212539-sec-0012}
---------------------

A total of 794 (90.0%) patients completed follow‐up; the median follow‐up duration was 28.6 months (interquartile range 13.1--40.2 months); death occurred in 162 (18.4%) patients, with 67 deaths due to HF; 374 (42.4%) patients were re‐hospitalized, with 235 re‐hospitalizations due to HF.

Kaplan--Meier survival curves and log‐rank test showed that the cumulative risk of all‐cause mortality (*P* \< 0.001) and all‐cause re‐hospitalization (*P* = 0.020) was significantly higher in the digoxin group than in the non‐digoxin group (*Figures* [*2*](#ehf212539-fig-0002){ref-type="fig"} *and* [*3*](#ehf212539-fig-0003){ref-type="fig"}), while the cumulative risk of HF mortality (*P* = 0.232) and HF re‐hospitalization (*P* = 0.098) was similar between the two groups.

![Kaplan--Meier cumulative risk of all‐cause mortality in patients with and without digoxin.](EHF2-7-138-g002){#ehf212539-fig-0002}

![Kaplan--Meier cumulative risk of all‐cause re‐hospitalization in patients with and without digoxin.](EHF2-7-138-g003){#ehf212539-fig-0003}

Cox proportional‐hazards regression analysis demonstrated that digoxin use was associated with higher risk of all‐cause mortality \[hazard ratio (HR) 1.76; 95% CI 1.27--2.44; *P* = 0.001\] and all‐cause re‐hospitalization (HR 1.27; 95% CI 1.03--1.57; *P* = 0.029) after adjustment for baseline age, SBP, LVEF, NYHA class, sodium, potassium, creatinine, haemoglobin, AF, and the use of ACEIs/ARBs, beta‐blockers and MRAs (*Table* [2](#ehf212539-tbl-0002){ref-type="table"}).

###### 

Multivariate Cox proportional‐hazards models for predictions of time to different endpoint events by use of digoxin

+------------------------------+-------------+-------------+--------+------------+-------+
| Outcomes                     | Events      | HR          | 95% CI | *P* value  |       |
|                              |             |             |        |            |       |
|                              | *n* (%)     |             |        |            |       |
+:=============================+=============+=============+========+============+=======+
| All‐cause mortality          | 73 (14.3%)  | 89 (23.9%)  | 1.76   | 1.27--2.44 | 0.001 |
+------------------------------+-------------+-------------+--------+------------+-------+
| HF mortality                 | 35 (6.9%)   | 32 (8.6%)   | 1.31   | 0.79--2.16 | 0.296 |
+------------------------------+-------------+-------------+--------+------------+-------+
| All‐cause re‐hospitalization | 195 (38.2%) | 179 (48.1%) | 1.27   | 1.03--1.57 | 0.029 |
+------------------------------+-------------+-------------+--------+------------+-------+
| HF re‐hospitalization        | 124 (24.3%) | 111 (29.8%) | 1.19   | 0.91--1.55 | 0.213 |
+------------------------------+-------------+-------------+--------+------------+-------+

Multivariate Cox regression model adjustment for baseline age, SBP, LVEF, NYHA class, sodium, potassium, creatinine, haemoglobin, atrial fibrillation (AF) and the use of ACEIs/ARBs, beta‐blockers and MRAs.

CI, confidence interval; HR, hazard ratio.

3.4. Interaction of digoxin use on outcomes in atrial fibrillation vs. non‐atrial fibrillation {#ehf212539-sec-0013}
----------------------------------------------------------------------------------------------

There were 232 patients (26.3%) with AF. The HFrEF patients were categorized into following four subgroups: 399 patients (45.2%) without AF and did not receive digoxin (Digoxin−AF−), 251 patients (28.5%) without AF but received digoxin (Digoxin+AF−), 111 patients (12.6%) with AF but did not receive digoxin (Digoxin−AF+), and 121 patients (13.7%) with AF and received digoxin (Digoxin+AF+). Rates of all‐cause mortality of Digoxin−AF−, Digoxin+AF−, Digoxin−AF+, and Digoxin+AF+ were 13.0%, 19.9%, 18.9%, and 32.2%, respectively; rates of HF mortality of Digoxin−AF−, Digoxin+AF−, Digoxin−AF+, and Digoxin+AF+ were 6.5%, 8.8%, 8.1%, and 8.3%, respectively; rates of all‐cause re‐hospitalization of Digoxin−AF−, Digoxin+AF−, Digoxin−AF+, and Digoxin+AF+ were 38.3%, 46.2%, 37.8%, and 52.1%, respectively; rates of HF re‐hospitalization of Digoxin−AF−, Digoxin+AF−, Digoxin−AF+, and Digoxin+AF+ were 25.1%, 31.1%, 21.6%, and 27.3%, respectively.

As shown in *Table* [3](#ehf212539-tbl-0003){ref-type="table"}, compared with the reference group (Digoxin+AF+), all‐cause mortality was lower in both the Digoxin−AF+ group (HR 0.48; 95% CI 0.28--0.83; *P* = 0.009) and Digoxin−AF− group (HR 0.42; 95% CI 0.27--0.65; *P* \< 0.001), and all‐cause re‐hospitalization risk was lower in the Digoxin−AF+ group (HR 0.64; 95% CI 0.43--0.95; *P* = 0.028) (*Table* [3](#ehf212539-tbl-0003){ref-type="table"}). And the Digoxin+AF− group had a 61% increase in all‐cause mortality risk when the Digoxin−AF− group served as a reference group (HR 1.61; 95% CI 1.08--2.40; *P* = 0.021). In short, digoxin is an independent predictor of all‐cause mortality in HFrEF patients, with both AF and non‐AF.

###### 

Hazard ratios and 95% CI of digoxin associated with cardiac endpoints for the subgroups

                All‐cause mortality     HF mortality        All‐cause re‐hospitalization   HF re‐hospitalization
  ------------- ----------------------- ------------------- ------------------------------ -----------------------
  Digoxin−AF−   0.42 (0.27--0.65)^\*^   0.88 (0.41--1.89)   0.83 (0.61--1.13)              1.07 (0.71--1.60)
  Digoxin+AF−   0.68 (0.44--1.05)       1.20 (0.55--2.64)   0.98 (0.71--1.34)              1.23 (0.81--1.86)
  Digoxin−AF+   0.48 (0.28--0.83)^\*^   0.86 (0.34--2.21)   0.64 (0.43--0.95)^\*^          0.77 (0.45--1.31)
  Digoxin+AF+   1                       1                   1                              1

Multivariate Cox regression model adjustment for age, SBP, LVEF, NYHA class, sodium, potassium, creatinine, haemoglobin, and the use of ACEIs/ARBs, beta‐blockers and MRAs.

CI, confidence interval.

*P* \< 0.05.

3.5. Impact of digoxin use on outcome in uses of other drugs {#ehf212539-sec-0014}
------------------------------------------------------------

Six hundred twenty (70.3%) patients received beta‐blockers. There were 258 patients in digoxin group and 362 patients in non‐digoxin group; the rates of all‐cause mortality, HF mortality, all‐cause re‐hospitalization, and HF re‐hospitalization were 16.1%, 7.4%, 41.5%, and 27.6%, respectively; and digoxin was significantly associated with a 90% increase in all‐cause mortality risk (HR 1.90; 95% CI 1.24--2.91; *P* = 0.003) (*Table* [4](#ehf212539-tbl-0004){ref-type="table"}).

###### 

Hazard ratios and 95% CI for different endpoint events of drugs (digoxin vs. non‐digoxin users)

                                        Non‐digoxin   Digoxin       HR     95% CI       *P* value
  ------------------------------------- ------------- ------------- ------ ------------ -----------
  Beta‐blockers                                                                         
  All‐cause mortality                   41 (11.3%)    59 (22.9%)    1.90   1.24--2.91   0.003
  HF mortality                          23 (6.4%)     23 (8.9%)     1.30   0.70--2.43   0.410
  All‐cause re‐hospitalization          135 (37.3%)   122 (47.3%)   1.16   0.89--1.51   0.274
  HF re‐hospitalization                 92 (25.4%)    79 (30.6%)    1.07   0.78--1.48   0.674
  ACEIs/ARBs                                                                            
  All‐cause mortality                   50 (12.2%)    57 (19.3%)    1.48   0.98--2.22   0.061
  HF mortality                          24 (5.9%)     24 (8.1%)     1.35   0.74--2.47   0.333
  All‐cause re‐hospitalization          149 (36.4%)   134 (45.3%)   1.26   0.99--1.62   0.066
  HF re‐hospitalization                 99 (24.2%)    88 (29.7%)    1.23   0.90--1.66   0.190
  MRAs                                                                                  
  All‐cause mortality                   62 (14.5%)    82 (23.0%)    1.68   1.20--2.37   0.003
  HF mortality                          33 (7.7%)     31 (8.7%)     1.28   0.77--2.13   0.346
  All‐cause re‐hospitalization          171 (39.9%)   170 (47.8%)   1.23   0.99--1.54   0.061
  HF re‐hospitalization                 115 (26.8%)   108 (30.3%)   1.17   0.89--1.54   0.254
  ACEIs/ARBs, beta‐blockers, and MRAs                                                   
  All‐cause mortality                   29 (10.9%)    41 (19.9%)    1.70   1.01--2.86   0.047
  HF mortality                          18 (6.8%)     17 (8.3%)     1.19   0.57--2.51   0.643
  All‐cause re‐hospitalization          100 (37.7%)   92 (44.7%)    1.16   0.85--1.57   0.356
  HF re‐hospitalization                 72 (27.2%)    62 (30.1%)    1.12   0.78--1.62   0.544

ACEIs, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CI, confidence interval; MRAs, mineralocorticoid receptor antagonists.

A total of 705 patients (79.9%) were treated with ACEIs/ARBs. Among the 296 patients in the digoxin group and 409 patients in the non‐digoxin group, death occurred in 107 (15.2%) patients, 48 (6.8%) patient deaths were due to HF; 283 (40.1%) patients were re‐hospitalized, and 187 (26.5%) re‐hospitalization was due to HF. The use of digoxin was associated with the increased trend of all‐cause mortality risk (HR 1.48; 95% CI 0.98--2.22; *P* = 0.061) (*Table* [4](#ehf212539-tbl-0004){ref-type="table"}).

Among those on treatment with MRAs (*n* = 785), 356 patients were in the digoxin group and 429 patients in the non‐digoxin group. The all‐cause mortality (HR 1.68; 95% CI 1.20--2.37; *P* = 0.003) was higher in the digoxin group compared with non‐digoxin group (*Table* [4](#ehf212539-tbl-0004){ref-type="table"}).

In those treated with ACEIs/ARBs, beta‐blockers, and MRAs (*n* = 471), 206 patients were in the digoxin group and 265 patients in the non‐digoxin group. Digoxin increased the risk of all‐cause mortality by 70% compared with that in the non‐digoxin group (HR 1.70; 95% CI 1.01--2.86; *P* = 0.047) (*Table* [4](#ehf212539-tbl-0004){ref-type="table"}).

4. Discussion {#ehf212539-sec-0015}
=============

On the basis of data derived from this nationwide registry study of HFrEF in China, we found that use of digoxin is associated with a higher risk of all‐cause mortality in HFrEF patients, irrespective of heart rhythm and use of other guideline‐recommended therapy.

Efficacy of digoxin in patients with HF has been studied previously in Western countries. In Digitalis Investigation Group (DIG), trial digoxin was not associated with increased risk of overall mortality; in fact, digoxin use was related to reduced risk of all‐cause re‐hospitalization and HF re‐hospitalization in patients with HF of LVEF ≤ 45%.[8](#ehf212539-bib-0008){ref-type="ref"} In the subgroup analysis of the DIG trial (NYHA Class III--IV symptoms, LVEF \< 25%, or cardiothoracic ratio \> 55%), digoxin significantly improved the outcomes of clinically important combined endpoints of mortality or hospitalizations in chronic HF patients.[22](#ehf212539-bib-0022){ref-type="ref"} Our analysis, however, suggested that digoxin use is associated with increased all‐cause mortality and all‐cause re‐hospitalization in HFrEF patients. Our finding is similar to that of a nationwide propensity score‐matched study in Denmark, which also showed that digoxin use was linked with an increased risk of all‐cause mortality in HF patients.[9](#ehf212539-bib-0009){ref-type="ref"} Similar results were also demonstrated in other studies.[10](#ehf212539-bib-0010){ref-type="ref"}, [11](#ehf212539-bib-0011){ref-type="ref"}, [12](#ehf212539-bib-0012){ref-type="ref"}

One important question is why efficacy and safety from DIG trial could not be reproduced in recent studies in real‐world settings. Several issues are worthy to be discussed. Firstly, the background therapy of DIG trial did not represent the contemporary guideline‐directed medical therapy (GDMT). As a matter of fact, data were not available regarding the use of beta‐blockers and MRAs in DIG trial. It is well known that beta‐blockers and MRAs could improve survival of HFrEF patients. Secondly, there was selection bias in the DIG trial in which around 40% of the study population were treated with digoxin prior to the study. This might ensure the tolerability in favour for digoxin. However, this is not the case in a real‐world scenario as in the case of this registry study. According to current guideline, digoxin could be initiated in patients who remain symptomatic despite recommended treatment with ACEIs/ARBs, beta‐blockers, MRAs, and diuretics when necessary. Thirdly, as is the nature of a randomized controlled trial such as the DIG trial, patients were monitored closely by a special study team, whereas this is not the case in the real world. Ideally, regular monitoring might increase the safety of digoxin use owing to the narrow therapeutic dose range of digoxin.

Another important question is why digoxin use is associated with increased all‐cause mortality in current study. Several possibilities exist. Patients in digoxin group in the present study were probably sicker than non‐digoxin group, as former patients had higher heart rate, higher prevalence of NYHA III--IV, lower EF, and more MRAs; all these factors might indicate that these patients may carry higher risk for mortality. Indeed, by applying the multivariable Cox regression, we tried to adjust the variables as much as we could. Moreover, the therapeutic effect and toxic effect of digoxin were known to be closely related to the serum digoxin concentration owing to its narrow therapeutic index. The Propensity Matched Study of the DIG trial suggested that digoxin at low serum digoxin concentration significantly reduced mortality and hospitalizations in HF patients.[23](#ehf212539-bib-0023){ref-type="ref"} In fact, up to 90.8% of patients in our cohort took digoxin at a dose of no more than 0.125 mg/day. However, we cannot exclude the possibility that Chinese patients with HF might tolerate less to digoxin than in Western countries owing to ethnicity.

In addition, the reasons for digoxin intake increased all‐cause mortality, and all‐cause re‐hospitalization but not HF mortality and HF re‐hospitalization is also worth exploring. One of the possible explanations is that patients with digoxin are more seriously ill and are more often have other accompanying non‐cardiovascular co‐morbidities. All these together make these patients prone to have increased all‐cause mortality and all‐cause re‐hospitalization. Regarding serum digoxin concentrations, unfortunately, we did not have such data, as serum digoxin concentration was not measured routinely in daily clinical practice if there was no clinical suspect of digoxin toxicity.

Our findings extended previous studies in four aspects. Firstly, compared with the Danish registry study, CN‐HF reported more contemporary HF management.[9](#ehf212539-bib-0009){ref-type="ref"} In the Danish registry study, rate of ACEIs/ARBs use was 54%, beta‐blockers was 39.5%, and MRAs was 20.0%, whereas in CN‐HF, rate of ACEIs/ARBs use was 79.9%,beta‐blockers was 70.3%, and MRAs was 89.0%. This difference not only reflects geographic heterogeneity in HF management but also makes our study more relevant at least for the Chinese HF population. Secondly, our study confirmed results from the Danish study indicating that digoxin is associated with increased all‐cause mortality in a real‐world setting regardless of geographic difference. This is particularly relevant as in China some TCMs were recommended to treat HF.[20](#ehf212539-bib-0020){ref-type="ref"} Thirdly, in our study, we were able to make a comprehensive assessment of possible impact of digoxin by concurrent use of temporary GDMT. This is a highly relevant issue for HFrEF population, as digoxin is administrated after optimal use of GDMT, which was not studied in the DIG trial. We evaluated possible interactions of impact of digoxin by AF. Despite that AF is one of the most common arrhythmias in HF patients and digoxin is often used to control the heart rate in patients with HFrEF and concomitant AF, the impact of digoxin on the prognosis of these patients is still controversial.[24](#ehf212539-bib-0024){ref-type="ref"}, [25](#ehf212539-bib-0025){ref-type="ref"} Our findings were in line with recent study that showed digoxin increasing mortality in AF patients with HF.[26](#ehf212539-bib-0026){ref-type="ref"}

There are some limitations in this study. Firstly, this study refers a small patient cohort because LVEF ≤ 40% was found only in a small population in CN‐HF register. A similar finding was reported in other Asian HF registries.[27](#ehf212539-bib-0027){ref-type="ref"}, [28](#ehf212539-bib-0028){ref-type="ref"}, [29](#ehf212539-bib-0029){ref-type="ref"} Secondly, our research data are derived from 45 different hospitals, which are highly heterogeneous. For example, although we have conducted strict, unified, and standardized training for participants in different hospitals, the specific treatment plan of patients depends on different clinicians. There are also significant difficulties in controlling confounding factors, although the multivariable Cox regression analysis is used to control confounding factors as much as possible, and we cannot control factors that are not included and may influence the results of this study. In other words, the conclusions were established on the premise that the existing confounding factors involved in this study were adjusted, so they still need to be further confirmed by randomized clinical trials. Thirdly, there are many kinds of TCMs; some of them are served as soups whereas others as capsule, depending on the characteristics of the patient. Generally, qili qiangxin capsule is one of the most common prescribed TCMs in HF. The TCMs in each of the 45 hospitals are different. We can only know from our research database whether these patients received TCMs but did not obtain the information about specific drug kind and usage. This article reflects the current status of treatment in patients with HF in China. To date, there are at least three types of TCMs that are believed to affect the metabolism of digoxin including: (i) ginseng‐containing preparations, which can directly excite myocardium and strengthen heart function, thus enhance each other when combined with digoxin, which is prone to digoxin toxicity; (ii) licorice‐enriched preparation that might reduce the K+ in the body and thus make the heart more sensitive to digoxin; and (iii) calcium‐containing preparation, which can enhance the effect of digoxin and thus increase the toxicity, causes arrhythmia and conduction block.[30](#ehf212539-bib-0030){ref-type="ref"} Finally, serum digoxin concentrations were not monitored and analysed. However, the strength of this study is data from a prospective HF registry in China where both population and care modality in HF may differ from Western countries.

5. Conclusions {#ehf212539-sec-0016}
==============

In this nationwide registry study of HFrEF, we found that use of digoxin was an independent predictor of all‐cause mortality in HFrEF patients, irrespective of contemporary guideline‐recommended therapy and in patients with AF and non‐AF.

Conflict of interest {#ehf212539-sec-0018}
====================

None declared.

Funding {#ehf212539-sec-0019}
=======

This study was supported by the National Science & Technology Pillar Program, 12th 5‐year plan of China (2011BAI11B10).

We would like to acknowledge all the investigators in the following research sites for making data available for public use. Qiaoqing Zhong. Chenzhou No. 1 People\'s Hospital, Chenzhou, ChinaYingmin Lu. Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chongming branch, Shanghai, ChinaGuohui Zhang. Zhenjiang First People\'s Hospital, Zhenjiang, ChinaLi Chen. Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaHuimin Gu. First People\'s Hospital of Kunshan, Kunshan, ChinaMeng Wei. Shanghai Sixth People\'s Hospital, Shanghai, ChinaLianglong Chen. Fujian Medical University Union Hospital, Fuzhou, ChinaJun Wang. Jing\'an District Central Hospital of Shanghai, Shanghai, ChinaZhenyu Yang. Wuxi People\'s Hospital, Wuxi, ChinaHuigen Jin. Putuo People\'s Hospital of Shanghai, Shanghai, ChinaXianliang Li. Zhangjiagang Hospital of Traditional Chinese Medicine, Zhangjiagang, ChinaZengyong Qiao. Shanghai Fengxian District Central Hospital, Shanghai, ChinaYingjun Yang. Jiashan First People\'s Hospital, Jiashan, ChinaYulan Zhao. The Second Affiliated Hospital of Zhenzhou University, Zhengzhou, ChinaRu Jia. The No.4 Hospital 1946 Jinan Shandong, Ji\'nan, ChinaBin Hong. Shanghai Qingpu District Central Hospital, Shanghai, ChinaFang Yuan. Shanghai Chest Hospital, Shanghai, ChinaJufei Wang. Fenghua Hospital, Fenghua, ChinaJin Ma. Yangpu Hospital, Tongji University, Shanghai, ChinaYu Xu. Henan Provincial People\'s Hospital, Zhengzhou, ChinaLiwen Li. Guangdong General Hospital, Guangzhou, ChinaMahmud Wahafu. The Second People\'s Hospital of Kashgar Prefecture, Kashi, Xinjiang, ChinaQin Yu. Zhongshan Hospital, Dalian University, Dalian, ChinaChangqian Wang. Shanghai Ninth People\'s Hospital, Shanghai, ChinaChangwu Ruan. Shanghai Eighth People\'s Hospital, Shanghai, ChinaHonggang Fu. Fuyuan People\'s Hospital, Qujing, ChinaXuebo Liu. Shanghai East Hospital, Tongji University, Shanghai, ChinaXin Xu. Wuxi No.2 People\'s Hospital, Wuxi, ChinaShaoping Chen. Changhai Hospital of Shanghai, Shanghai, ChinaQiliang Liu. Putuo District Center Hospital, Shanghai, ChinaBei Shi. Hospital of Zunyi Medical College, Zunyi, ChinaJiahong Xu. Tongji Hospital, Tongji University, Wuhan, ChinaZhenyue Chen. Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

[^1]: These authors contributed equally to this work.
